PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2026Journal of Pain Research0 citationsOpen Access

Long-Acting versus Short-Acting Opioids and Opioid-Related Disorders in Chronic Non-Cancer Pain: A Claims Data Analysis in Germany

SBSabrina BrinkmöllerRPRegina Poß-DoeringCSCornelia Straßner

Key Points

Key points are not available for this paper at this time.

Abstract

Background: Chronic non-cancer pain is common in primary care and may be managed with long-term opioid therapy. The German guideline “Long-term Use of Opioids for Chronic Non-Cancer Pain” provides recommendations for such treatment. The role of opioid formulation (long-acting vs. short-acting) and the association with opioid-related disorders remains underexplored. This study aims to explore associations between opioid formulation and opioid-related disorders in patients with chronic non-cancer pain receiving long-term opioid therapy in German general practices. Methods: We conducted a retrospective cross-sectional claims data analysis using data from one statutory health insurer in Baden-Württemberg (AOK), Germany, for the year 2021. The analysis included patients aged ≥ 18 years who received at least one oral or transdermal opioid prescription in all four quarters. Exclusion criteria were malignant diseases or palliative care. The outcome was opioid-related disorder (ICD-10 category F11.-). Multivariable logistic regression analyses were performed to identify predictors. Results: Multiple models were calculated. The main model included a total of 34,205 patients. The mean age was 70 years, and 65% were female. Overall, 3.1% of patients were diagnosed with an opioid-related disorder. Weak opioids were most frequently prescribed. Long-acting opioids predominated. Higher odds of opioid-related disorders were observed in patients with substance use disorders involving such as sedatives (OR = 5.6, 95% CI: 4.48– 7.01) or alcohol (OR = 2.2, 95% CI: 1.82– 2.66). Short-acting opioids (OR = 2.0, 95% CI: 1.53– 2.48) and combined long- and short-acting therapy (OR = 3.5, 95% CI: 2.38– 5.00) were associated with higher odds of opioid-related disorders compared with long-acting opioids (all p < 0.001). Conclusion: The results suggest that short-acting opioids, either alone or as part of combination therapy, may be more strongly associated with opioid-related disorders in patients with chronic non-cancer pain and long-term opioid therapy than long-acting opioids alone. Further research is needed to clarify these relationships and their underlying causes. Keywords: chronic non-cancer pain, primary care, general practice, long-term opioid therapy, opioid-related disorders, opioid formulation, long-acting opioids, short-acting opioids, Germany

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Brinkmöller et al. (2026) studied this question.

synapsesocial.com/papers/6a215fa6f6aa648d3a57ed78https://doi.org/10.2147/jpr.s599161
Ask AI
Helpful
Bookmark
Share
View Full Paper